Literature DB >> 18272798

Simulated type II superior labral anterior posterior lesions do not alter the path of glenohumeral articulation: a cadaveric biomechanical study.

Thomas Youm1, James E Tibone, Neal S ElAttrache, Michelle H McGarry, Thay Q Lee.   

Abstract

BACKGROUND: Previous studies have demonstrated increased glenohumeral translations with simulated type II superior labral anterior posterior lesions, which may explain the sensation of instability in the overhead-throwing athlete. It is unknown whether this amount of increased translation alters glenohumeral kinematics.
PURPOSE: To determine whether type II superior labral anterior posterior lesions significantly alter glenohumeral kinematics as defined by path of glenohumeral articulation in a simulated cadaveric model of the throwing shoulder. STUDY
DESIGN: Controlled laboratory study.
METHODS: Six cadaveric shoulders were tested for glenohumeral rotational range of motion and translation using a custom shoulder testing system and the Microscribe 3DLX. The path of glenohumeral articulation was measured by calculating the humeral head center with respect to the glenoid articular surface at maximal internal rotation, 30 degrees, 60 degrees, 90 degrees, and maximal external rotation. Data were recorded for vented intact shoulders, shoulders with arthroscopically created type II superior labral anterior posterior lesions, and shoulders with arthroscopically repaired superior labral anterior posterior lesions.
RESULTS: A subtle but significant increase in external rotation (2.7 degrees) was seen after creating a type II lesion. Small increases in glenohumeral translation were found in the anterior (0.9 mm) and inferior (0.9 mm) directions with application of a 15-N force in the superior labral anterior posterior group. Increases in glenohumeral rotation and translation were restored to the intact state after repair of the lesion. No significant differences were found in the path of glenohumeral articulation for the superior labral anterior posterior condition compared with the intact shoulder.
CONCLUSION: The small amounts of increased external rotation and translation found with arthroscopically created type II superior labral anterior posterior lesions do not significantly affect glenohumeral kinematics in this passive motion model as quantified by the path of glenohumeral articulation. CLINICAL RELEVANCE: Findings suggest that in the absence of pain or mechanical symptoms, type II superior labral anterior posterior lesions that do not significantly involve the superior and middle glenohumeral ligaments may not need surgical repair.

Entities:  

Mesh:

Year:  2008        PMID: 18272798     DOI: 10.1177/0363546507312169

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  5 in total

1.  Anteroposterior translation of the glenohumeral joint in various pathologies: differences between shoulder MRI in the adducted neutral rotation and abducted externally rotated positions.

Authors:  Kyung Cheon Kim; Yong Girl Rhee; Jin Young Park; Hyun Dae Shin; Soo Min Cha; Jun Yeong Park; Sun Cheol Han; Jae Hoon Yang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-09-27       Impact factor: 4.342

2.  Specimen-specific method for quantifying glenohumeral joint kinematics.

Authors:  Yeon Soo Lee; Thay Q Lee
Journal:  Ann Biomed Eng       Date:  2010-05-25       Impact factor: 3.934

3.  An Age and Activity Algorithm for Treatment of Type II SLAP Tears.

Authors:  Michael D Charles; David R Christian; Brian J Cole
Journal:  Open Orthop J       Date:  2018-07-31

4.  Superior labral anterior posterior lesions of the shoulder.

Authors:  Joby Jacob George Malal; Yousaf Khan; Graville Farrar; Mohammed Waseem
Journal:  Open Orthop J       Date:  2013-09-06

5.  Glenohumeral Function of the Long Head of the Biceps Muscle: An Electromyographic Analysis.

Authors:  Peter N Chalmers; Johannes Cip; Robert Trombley; Brian J Cole; Markus A Wimmer; Anthony A Romeo; Nikhil N Verma
Journal:  Orthop J Sports Med       Date:  2014-02-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.